In order to enhance the technical innovation capacity of enterprises, build a peptide drug technology development platform and promote the transformation of research achievements, on the afternoon of April 14, Shenzhen Institute of Advanced Technology (SIAT) of Chinese Academy of Sciences, SIAT University (tentative name) and Hybio Pharmaceutical held a strategic cooperation signing & inauguration ceremony for the co-building of a “Synthetic Biology and Peptide Drug Joint Research Center”, which has infused a strong driving force into the development of synthetic biology and peptide industry.
The signing ceremony was presided over by Huang Xiaohua, deputy director of the Development Department of SIAT. Zeng Shaogui, chairman of Hybio Pharmaceutical, and Zhang Xian’en, honorary president of the School of Synthetic Biology of SIAT University, signed a strategic cooperation contract on behalf of both sides.
The signing ceremony
The inauguration ceremony of the Joint Research Center was attended by Zhao Yanyan, a member of the Party group and deputy head of the government of Longhua District, Lv Jigang, the director of the district’s scientific innovation bureau, Fan Jianping, an academician with International Eurasian Academy of Sciences, president of SIAT and director of the preparatory office of SIAT University, Zhang Xian’en, honorary president of the School of Synthetic Biology of SIAT University, Huang Xiaohua, deputy director of the Development Department of SIAT, Chen Minghai, an associate researcher with the Quantitative Synthetic Biology Research Center of SIAT, Zeng Shaogui, chairman, Zeng Shaoqiang, vice chairman, Yu Pinxiang, CEO, Tang Yangming, executive vice-president of Hybio Pharmaceutical, etc.
The inauguration ceremony
Adhering to the strategy of “combining generic and innovative drugs”, Hybio Pharmaceutical strives to achieve innovation and transformation while developing generic drugs well. Thus far, eight products of the company have passed the consistency evaluation. It has cooperated with top domestic research institutes to develop an anti-Covid19 nasal spray, taking a key step towards the development of innovative drugs. It has cooperated with Reveda, a subsidiary of MicroPort Group, to expand the field of microneedle transdermal administration and further improve its layout of innovative drugs and dosage forms. It has joined hands with the Third People’s Hospital of Shenzhen and National Clinical Research Center for Infectious Diseases to promote the clinical research and application of new drugs, which has become an important transition stage for its strategic layout of “generic and innovative drugs”. The win-win alliance with SIAT this time was an important step for Hybio Pharmaceutical to leap from a manufacturer of generic drugs to a manufacturer of innovative drugs.
Unleashing the advantages in the fields of synthetic biology and peptide drugs
The development of peptide drugs has involved many fields of disease prevention and treatment, such as anti-tumor peptides, antiviral peptides, antimicrobial peptides, peptide vaccines, internal secretion, digestion and hemostasis, which boasts a good potential of growth and a promising prospect.
Based on the concept of engineering design, synthetic biology launches targeted design, transformation and re-synthesis of organisms, which is a frontier field of life science and interdisciplinary science today. It is developing rapidly, spawning the next generation of biotechnology and leading the future biological economy.
Facilitating the launch of more research projects and the commercialization of scientific and technological achievements
Hybio Pharmaceutical is a national high-tech enterprise specializing in the development, production and sales of peptide drugs, with rich industrialization experience. Shenzhen Institute of Advanced Technology and SIAT University boast a solid strength in synthetic biology research. The cooperation this time will provide a strong driving force for the development and improvement of synthetic biology and peptide industry.
According to the agreement, the three parties will co-build a Synthetic Biology and Peptide Drugs Joint Research Center, work together around the research of peptide drugs such as anti-infection, anti-tumor, internal secretion and pain killer, and develop new peptide drugs with good medicinal properties and good efficacy. Both sides will adopt synthetic biology methods along with rational design, molecular evolution and high-throughput screening platforms to carry out research on high-quality peptide drugs and improve the quality of peptide drugs.
Promoting the innovative development of synthetic biology and peptide industry
At the signing ceremony, Fan Jianping said, the SIAT focused on the requirements of the times on the deep integration of industrial chains, insisted on the integrated design and advancement of science and industry, and taken the lead to explore the “Butterfly Mode” of “0-1-10-∞”. By concentrating elements such as education and academy, research and transformation and open facilities, it has maintained a close interaction with the government and market to form several open innovation element aggregates, and accelerate achievement transformation and industrial agglomeration. SIAT has many advanced scientific research talents and innovation achievements. The Joint Research Center is an important platform for the SIAT’s achievement transformation and industrial collaboration and innovation, which can allow the three parties to further explore new technology and develop new products in their respective fields. Hopefully, they can give full play to their respective advantages and launch in-depth cooperation to achieve mutual benefits and win-win results.
Fan Jianping
Zeng Shaogui said that the strategic cooperation with SIAT and SIAT University had a broad prospect in application and huge market space. Hybio Pharmaceutical will adhere to the strategy of “combining generic and innovative drugs” and accelerate its innovation and transformation in co-building a “Synthetic Biology and Peptide Drugs Joint Research Center” with SIAT. It will deepen the R&D and seek technological breakthroughs in innovative drugs such as peptide drugs to promote the industrialization of major research achievements and make a bigger contribution to the innovation and development of synthetic biology and peptide industry.
Zeng Shaogui
Posing for a group photo
